This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sigal, A. Articles by Rotter, V. Search for Related Content PubMed PubMed Citation Articles by Sigal, A. Articles by Rotter, V.

Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel 76100

The p53 guardian of the genome is inactivated in the majority of cancers, mostly through missense mutations that cause single residue changes in the DNA binding core domain of the protein. Not only do such mutations result in the abrogation of wild-type p53 activity, but the expressed p53 mutant proteins also tend to gain oncogenic functions, such as interference with wild-type p53-independent apoptosis. Because p53 mutants are highly expressed in cancer cells and not in normal cells, their reactivation to wild-type p53 function may eliminate the cancer by apoptosis or another p53-dependent mechanism. Several studies that embarked on this quest for reactivation have succeeded in restoring wild-type p53 activity to several p53 mutants. However, mutants with more extensive structural changes in the DNA binding core domain may be refractory to reactivation to the wild-type p53 phenotype. Therefore, understanding the structure and functions of oncogenic p53 mutants may lead to more potent reactivation modalities or to the ability to eliminate mutant p53 gain of function.

This article has been cited by other articles:

				Y. Y. Waldman, T. Tuller, R. Sharan, and E. Ruppin TP53 Cancerous Mutations Exhibit Selection for Translation Efficiency Cancer Res., November 15, 2009; 69(22): 8807 - 8813. [Abstract] [Full Text] [PDF]

				T.-H. Kim, S. Y. Lee, J. H. Rho, N. Y. Jeong, Y. H. Soung, W. S. Jo, D.-Y. Kang, S.-H. Kim, and Y. H. Yoo Mutant p53 (G199V) Gains Antiapoptotic Function through Signal Transducer and Activator of Transcription 3 in Anaplastic Thyroid Cancer Cells Mol. Cancer Res., October 1, 2009; 7(10): 1645 - 1654. [Abstract] [Full Text] [PDF]

				S. Haupt, S. di Agostino, I. Mizrahi, O. Alsheich-Bartok, M. Voorhoeve, A. Damalas, G. Blandino, and Y. Haupt Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53 Cancer Res., June 1, 2009; 69(11): 4818 - 4826. [Abstract] [Full Text] [PDF]

				D. F. Calvisi, H. Donninger, M. D. Vos, M. J. Birrer, L. Gordon, V. Leaner, and G. J. Clark NORE1A Tumor Suppressor Candidate Modulates p21CIP1 via p53 Cancer Res., June 1, 2009; 69(11): 4629 - 4637. [Abstract] [Full Text] [PDF]

				E. Guida, A. Bisso, C. Fenollar-Ferrer, M. Napoli, C. Anselmi, J. E. Girardini, P. Carloni, and G. Del Sal Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells Cancer Res., August 15, 2008; 68(16): 6550 - 6558. [Abstract] [Full Text] [PDF]

				G. Dhar, S. Banerjee, K. Dhar, O. Tawfik, M. S. Mayo, P. J. VanVeldhuizen, and S. K. Banerjee Gain of Oncogenic Function of p53 Mutants Induces Invasive Phenotypes in Human Breast Cancer Cells by Silencing CCN5/WISP-2 Cancer Res., June 15, 2008; 68(12): 4580 - 4587. [Abstract] [Full Text] [PDF]

				T. Terzian, Y.-A. Suh, T. Iwakuma, S. M. Post, M. Neumann, G. A. Lang, C. S. Van Pelt, and G. Lozano The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss Genes & Dev., May 15, 2008; 22(10): 1337 - 1344. [Abstract] [Full Text] [PDF]

				A. R. Cuddihy, F. Jalali, C. Coackley, and R. G. Bristow WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells Mol. Cancer Ther., April 1, 2008; 7(4): 980 - 992. [Abstract] [Full Text] [PDF]

				Y. Li, F. Guessous, S. Kwon, M. Kumar, O. Ibidapo, L. Fuller, E. Johnson, B. Lal, I. Hussaini, Y. Bao, et al. PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations Cancer Res., March 15, 2008; 68(6): 1723 - 1731. [Abstract] [Full Text] [PDF]

				S. Y. Nam, M. K. Lee, and K. Sabapathy The tumour-suppressor p53 is not required for pancreatic cell death during diabetes and upon irradiation J. Physiol., January 15, 2008; 586(2): 407 - 417. [Abstract] [Full Text] [PDF]

				S. Choi and J.N. Myers Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy Journal of Dental Research, January 1, 2008; 87(1): 14 - 32. [Abstract] [Full Text] [PDF]

				E. Kalo, Y. Buganim, K. E. Shapira, H. Besserglick, N. Goldfinger, L. Weisz, P. Stambolsky, Y. I. Henis, and V. Rotter Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor {beta}1 (TGF-{beta}1) Signaling Pathway by Repressing the Expression of TGF-{beta} Receptor Type II Mol. Cell. Biol., December 1, 2007; 27(23): 8228 - 8242. [Abstract] [Full Text] [PDF]

				N. Lukashchuk and K. H. Vousden Ubiquitination and Degradation of Mutant p53 Mol. Cell. Biol., December 1, 2007; 27(23): 8284 - 8295. [Abstract] [Full Text] [PDF]

				A. Marusyk, L. J. Wheeler, C. K. Mathews, and J. DeGregori p53 Mediates Senescence-Like Arrest Induced by Chronic Replicational Stress Mol. Cell. Biol., August 1, 2007; 27(15): 5336 - 5351. [Abstract] [Full Text] [PDF]

				S. A. Danziger, J. Zeng, Y. Wang, R. K. Brachmann, and R. H. Lathrop Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants Bioinformatics, July 1, 2007; 23(13): i104 - i114. [Abstract] [Full Text] [PDF]

				K. D. Scott, S. Nath-Sain, M. D. Agnew, and P. A. Marignani LKB1 Catalytically Deficient Mutants Enhance Cyclin D1 Expression Cancer Res., June 15, 2007; 67(12): 5622 - 5627. [Abstract] [Full Text] [PDF]

				S. W.P. Wijnhoven, E. N. Speksnijder, X. Liu, E. Zwart, C. Th. M. vanOostrom, R. B. Beems, E. M. Hoogervorst, M. M. Schaap, L. D. Attardi, T. Jacks, et al. Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage Cancer Res., May 15, 2007; 67(10): 4648 - 4656. [Abstract] [Full Text] [PDF]

				F. Vikhanskaya, M. K. Lee, M. Mazzoletti, M. Broggini, and K. Sabapathy Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53 Nucleic Acids Res., March 19, 2007; 35(6): 2093 - 2104. [Abstract] [Full Text] [PDF]

				L. Weisz, A. Damalas, M. Liontos, P. Karakaidos, G. Fontemaggi, R. Maor-Aloni, M. Kalis, M. Levrero, S. Strano, V. G. Gorgoulis, et al. Mutant p53 Enhances Nuclear Factor {kappa}B Activation by Tumor Necrosis Factor {alpha} in Cancer Cells Cancer Res., March 15, 2007; 67(6): 2396 - 2401. [Abstract] [Full Text] [PDF]

				R. P. C. Wong, W. P. Tsang, P. Y. Chau, N. N. Co, T. Y. Tsang, and T. T. Kwok p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 Mol. Cancer Ther., March 1, 2007; 6(3): 1054 - 1061. [Abstract] [Full Text] [PDF]

				M. Mattia, V. Gottifredi, K. McKinney, and C. Prives p53-Dependent p21 mRNA Elongation Is Impaired when DNA Replication Is Stalled Mol. Cell. Biol., February 15, 2007; 27(4): 1309 - 1320. [Abstract] [Full Text] [PDF]

				L. R. Dearth, H. Qian, T. Wang, T. E. Baroni, J. Zeng, S. W. Chen, S. Y. Yi, and R. K. Brachmann Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers Carcinogenesis, February 1, 2007; 28(2): 289 - 298. [Abstract] [Full Text] [PDF]

				J Peltonen, J A Welsh, and K H Vahakangas Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene? Human and Experimental Toxicology, January 1, 2007; 26(1): 9 - 18. [Abstract] [PDF]

				D. Goldschneider, E. Horvilleur, L.-F. Plassa, M. Guillaud-Bataille, K. Million, E. Wittmer-Dupret, G. Danglot, H. d. The, J. Benard, E. May, et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma Nucleic Acids Res., November 14, 2006; 34(19): 5603 - 5612. [Abstract] [Full Text] [PDF]

				E. Lopez-Knowles, S. Hernandez, M. Kogevinas, J. Lloreta, A. Amoros, A. Tardon, A. Carrato, S. Kishore, C. Serra, N. Malats, et al. The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors. Clin. Cancer Res., October 15, 2006; 12(20): 6029 - 6036. [Abstract] [Full Text] [PDF]

				A. Calcabrini, J. M. Garcia-Martinez, L. Gonzalez, M. J. Tendero, M. T. A. Ortuno, P. Crateri, A. Lopez-Rivas, G. Arancia, P. Gonzalez-Porque, and J. Martin-Perez Inhibition of proliferation and induction of apoptosis in human breast cancer cells by lauryl gallate Carcinogenesis, August 1, 2006; 27(8): 1699 - 1712. [Abstract] [Full Text] [PDF]

				A. Valbuena, F. M. Vega, S. Blanco, and P. A. Lazo p53 Downregulates Its Activating Vaccinia-Related Kinase 1, Forming a New Autoregulatory Loop. Mol. Cell. Biol., July 1, 2006; 26(13): 4782 - 4793. [Abstract] [Full Text] [PDF]

				S. P. Hussain and C. C. Harris p53 Biological Network: Chronic Inflammation and Cancer Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 249 - 254. [Full Text] [PDF]

				D. Menendez, A. Inga, and M. A. Resnick The Biological Impact of the Human Master Regulator p53 Can Be Altered by Mutations That Change the Spectrum and Expression of Its Target Genes. Mol. Cell. Biol., March 1, 2006; 26(6): 2297 - 2308. [Abstract] [Full Text] [PDF]

				Y. Liu and W. F. Bodmer From the Cover: Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines PNAS, January 24, 2006; 103(4): 976 - 981. [Abstract] [Full Text] [PDF]

				M. J. Scian, K. E. R. Stagliano, M. A. E. Anderson, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb Tumor-Derived p53 Mutants Induce NF-{kappa}B2 Gene Expression Mol. Cell. Biol., November 15, 2005; 25(22): 10097 - 10110. [Abstract] [Full Text] [PDF]

				E. L. Jackson, K. P. Olive, D. A. Tuveson, R. Bronson, D. Crowley, M. Brown, and T. Jacks The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer Cancer Res., November 15, 2005; 65(22): 10280 - 10288. [Abstract] [Full Text] [PDF]

				T. Göhler, S. Jäger, G. Warnecke, H. Yasuda, E. Kim, and W. Deppert Mutant p53 proteins bind DNA in a DNA structure-selective mode Nucleic Acids Res., February 18, 2005; 33(3): 1087 - 1100. [Abstract] [Full Text] [PDF]

				I Paron, C D'Ambrosio, A Scaloni, M T Berlingieri, P L Pallante, A Fusco, N Bivi, G Tell, and G Damante A differential proteomic approach to identify proteins associated with thyroid cell transformation J. Mol. Endocrinol., February 1, 2005; 34(1): 199 - 207. [Abstract] [Full Text] [PDF]

				M. J. Scian, K. E. R. Stagliano, M. A. Ellis, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb Modulation of Gene Expression by Tumor-Derived p53 Mutants Cancer Res., October 15, 2004; 64(20): 7447 - 7454. [Abstract] [Full Text] [PDF]

				Z. R. A. Razak, R. J. Varkonyi, M. Kulp-McEliece, C. Caslini, J. R. Testa, M. E. Murphy, and D. Broccoli p53 Differentially Inhibits Cell Growth Depending on the Mechanism of Telomere Maintenance Mol. Cell. Biol., July 1, 2004; 24(13): 5967 - 5977. [Abstract] [Full Text] [PDF]

				C.-Q. Li, A. I. Robles, C. L. Hanigan, L. J. Hofseth, L. J. Trudel, C. C. Harris, and G. N. Wogan Apoptotic Signaling Pathways Induced by Nitric Oxide in Human Lymphoblastoid Cells Expressing Wild-Type or Mutant p53 Cancer Res., May 1, 2004; 64(9): 3022 - 3029. [Abstract] [Full Text] [PDF]

				S. Pospisilova, C. Siligan, J. Ban, G. Jug, and H. Kovar Constitutive and DNA Damage Inducible Activation of pig3 and MDM2 Genes by Tumor-Derived p53 Mutant C277Y Mol. Cancer Res., May 1, 2004; 2(5): 296 - 304. [Abstract] [Full Text] [PDF]

				J. C. Schroeder, K. Conway, Y. Li, K. Mistry, D. A. Bell, and J. A. Taylor p53 Mutations in Bladder Cancer: Evidence for Exogenous versus Endogenous Risk Factors Cancer Res., November 1, 2003; 63(21): 7530 - 7538. [Abstract] [Full Text] [PDF]

				F. J. Kaye and T. Komiya New Leads Suggest a Clinically Relevant Genotype-Phenotype Relationship for the p53 Gene J Natl Cancer Inst, July 2, 2003; 95(13): 926 - 927. [Full Text] [PDF]

				S. A. Ahrendt, Y. Hu, M. Buta, M. P. McDermott, N. Benoit, S. C. Yang, L. Wu, and D. Sidransky p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study J Natl Cancer Inst, July 2, 2003; 95(13): 961 - 970. [Abstract] [Full Text] [PDF]

				E. Blanc, D. Goldschneider, E. Ferrandis, M. Barrois, G. Le Roux, S. Leonce, S. Douc-Rasy, J. Benard, and G. Raguenez MYCN Enhances P-gp/MDR1 Gene Expression in the Human Metastatic Neuroblastoma IGR-N-91 Model Am. J. Pathol., July 1, 2003; 163(1): 321 - 331. [Abstract] [Full Text] [PDF]

				J. Breton, F. Sichel, A. Abbas, J. Marnay, D. Arsene, and M. Lechevrel Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France) Mutagenesis, May 1, 2003; 18(3): 299 - 306. [Abstract] [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]

				D. Falke, M. Fisher, D. Ye, and R. L. Juliano Design of artificial transcription factors to selectively regulate the pro-apoptotic bax gene Nucleic Acids Res., February 1, 2003; 31(3): e10 - e10. [Abstract] [Full Text] [PDF]

				L. A. Martinez, I. Naguibneva, H. Lehrmann, A. Vervisch, T. Tchenio, G. Lozano, and A. Harel-Bellan Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways PNAS, November 12, 2002; 99(23): 14849 - 14854. [Abstract] [Full Text] [PDF]

				C.-Q. Li, L. J. Trudel, and G. N. Wogan Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53 PNAS, August 6, 2002; 99(16): 10364 - 10369. [Abstract] [Full Text] [PDF]

				S. Strano, G. Fontemaggi, A. Costanzo, M. G. Rizzo, O. Monti, A. Baccarini, G. Del Sal, M. Levrero, A. Sacchi, M. Oren, et al. Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities J. Biol. Chem., May 17, 2002; 277(21): 18817 - 18826. [Abstract] [Full Text] [PDF]

				A. Bravard, A. Ageron-Blanc, S. Alvarez, P. Drane, Y. le Rhun, F. Paris, C. Luccioni, and E. May Correlation between antioxidant status, tumorigenicity and radiosensitivity in sister rat cell lines Carcinogenesis, May 1, 2002; 23(5): 705 - 711. [Abstract] [Full Text] [PDF]

				Y. Iwanaga and K.-T. Jeang Expression of Mitotic Spindle Checkpoint Protein hsMAD1 Correlates with Cellular Proliferation and Is Activated by a Gain-of-Function p53 Mutant Cancer Res., May 1, 2002; 62(9): 2618 - 2624. [Abstract] [Full Text] [PDF]

				J. Smeds, P. Berggren, X. Ma, Z. Xu, K. Hemminki, and R. Kumar Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16INK4a and p14ARF ) and p53 genes are major targets for inactivation Carcinogenesis, April 1, 2002; 23(4): 645 - 655. [Abstract] [Full Text] [PDF]

				H. Stopper and W. K. Lutz Induction of micronuclei in human cell lines and primary cells by combination treatment with {gamma}-radiation and ethyl methanesulfonate Mutagenesis, March 1, 2002; 17(2): 177 - 181. [Abstract] [Full Text] [PDF]

				A. Yuan, C.-J. Yu, K.-T. Luh, S.-H. Kuo, Y.-C. Lee, and P.-C. Yang Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2002; 20(4): 900 - 910. [Abstract] [Full Text] [PDF]

				B. D. Jeffy, R. B. Chirnomas, E. J. Chen, J. M. Gudas, and D. F. Romagnolo Activation of the Aromatic Hydrocarbon Receptor Pathway Is Not Sufficient for Transcriptional Repression of BRCA-1: Requirements for Metabolism of Benzo[a]pyrene to 7r,8t-Dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene Cancer Res., January 1, 2002; 62(1): 113 - 121. [Abstract] [Full Text] [PDF]

				J. Sampath, D. Sun, V. J. Kidd, J. Grenet, A. Gandhi, L. H. Shapiro, Q. Wang, G. P. Zambetti, and J. D. Schuetz Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1 J. Biol. Chem., October 12, 2001; 276(42): 39359 - 39367. [Abstract] [Full Text] [PDF]

				A. I. Robles, N. A. Bemmels, A. B. Foraker, and C. C. Harris APAF-1 Is a Transcriptional Target of p53 in DNA Damage-induced Apoptosis Cancer Res., September 1, 2001; 61(18): 6660 - 6664. [Abstract] [Full Text] [PDF]

				M. S. Rieber, U. Zangemeister-Wittke, and M. Rieber p53-independent Induction of Apoptosis in Human Melanoma Cells by a bcl-2/bcl-xL Bispecific Antisense Oligonucleotide Clin. Cancer Res., May 1, 2001; 7(5): 1446 - 1451. [Abstract] [Full Text]

				C. Klein, G. Georges, K.-P. Kunkele, R. Huber, R. A. Engh, and S. Hansen High Thermostability and Lack of Cooperative DNA Binding Distinguish the p63 Core Domain from the Homologous Tumor Suppressor p53 J. Biol. Chem., September 28, 2001; 276(40): 37390 - 37401. [Abstract] [Full Text] [PDF]